Pharma is losing its allies in Congress, with many leaving or likely to leave by 2025. The pharmaceutical industry faced challenges when Democrats passed a drug pricing law in 2022, and now even longtime friends are departing. Six key allies with a collective 160 years of congressional experience are exiting, leaving knowledge gaps and key positions on health care committees to be filled. This shift could impact the industry’s ability to navigate policy changes in the future. To receive regular updates on health and medicine politics, sign up for STAT’s newsletter.
Source link
The pharmaceutical industry keeps losing Washington friends
